Mirzaten Q-Tab (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonizing postsynaptic 5‑HT2, 5‑HT3 and histamine H1 receptors. This dual action enhances serotonergic and noradrenergic neurotransmission while providing a sedative effect that can improve sleep.

The appropriate dose of Mirzaten Q-Tab is determined by the prescribing clinician based on the individual’s clinical condition, response to therapy, and tolerability. Dosage adjustments are made according to professional guidelines and patient needs.

The safety of mirtazapine in pregnancy and lactation has not been definitively established. Healthcare providers should weigh potential benefits against possible risks and consider alternative treatments when treating pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine has a distinct receptor profile that often results in greater sedation and appetite stimulation. It may be preferred when insomnia or weight loss are concerns, but individual response and side‑effect tolerance guide the choice of therapy.

Mirzaten Q-Tab should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and store them out of reach of children.

Mirzaten Q-Tab is taken orally, usually once daily in the evening with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include the potential for agranulocytosis, severe hepatic injury, and the emergence of suicidal thoughts or behaviors, especially during the initial treatment period. Patients should be monitored closely for any signs of infection, liver dysfunction, or worsening mood.

Mirtazapine is contraindicated in patients who are currently taking monoamine oxidase inhibitors (MAOIs) or have a known hypersensitivity to the drug. Caution is also advised for individuals with severe hepatic impairment, uncontrolled hypertension, or a history of seizures.